Publication
Venetoclax plus pediatric regimen in adolescents and adults with Ph-negative acute lymphoblastic leukemia.
Xiaoyuan Gong, Yuntao Liu, Qiuyun Fang, Runxia Gu, Kaiqi Liu, Dong Lin, Chunlin Zhou, Guangji Zhang, Benfa Gong, Shuning Wei, Yan Li, Shouyun Li, Ying Wang, Shaowei Qiu, Bingcheng Liu, Ying Wang, Yingchang Mi, Hui Wei, Jianxiang Wang
- Source
- PubMed
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260930-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
The B-cell lymphoma 2 inhibitor venetoclax has shown promise in acute lymphoblastic leukemia (ALL), but its role in first-line therapy for newly diagnosed (ND) Philadelphia chromosome-negative (Ph-) ALL is undefined. In this prospective phase 2 study, 167 adolescents and adults (aged 14-60 years)…
Read on PubMedLinked entities
Linked entities (2)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 1
- trialNCT05660473registry_reference1.00
Candidate 1
- cancerLeukemiadictionary0.60
Registered trialsNCT05660473
Curated evidence
Evidence citing this paper (0)
Data not yet available